Two new looks at sweeteners and the gut, and neither delivers a clean verdict

Cambridge researchers screened 39 sweeteners against 25 gut bacterial species in vitro. Around 75% altered growth in at least one species, and the screen identified 102 interactions in which a sweetener behaved differently in combination with caffeine, drugs, or other additives. One example: isosteviol combined with duloxetine suppressed Roseburia intestinalis and Parabacteroides merdae. The work was published in Molecular Systems Biology.

Separately, a narrative review in Nutrients covered eight artificial sweetener categories: saccharin, cyclamate, aspartame, acesulfame K, sucralose, neotame, neohesperidin DC, and mixed exposures. Its stated conclusion: "Current research evidence does not support a class-wide conclusion that NAS are uniformly harmful or safe."

Taken together, effects appear to be compound specific and dose specific rather than a property of sweeteners as a class.

The numbers

Sweeteners screened against 25 gut bacterial species	39
Sweeteners altering growth in at least one species	around 75%
Interactions where a sweetener behaved differently in combination	102
Sweetener categories covered by the review	8

What this does not show

That sweeteners damage the human gut. The Cambridge screen is in vitro. Growth changes in lab cultures are not health outcomes in people, and the study's own release says so directly.
That sweeteners are cleared either. The review supports neither a uniformly harmful nor a uniformly safe verdict. Effects are compound specific and dose specific.
That the review pools evidence. The Nutrients paper is a narrative review with no systematic or PRISMA designation. It is synthesis, not pooled data.

Caveats worth holding

The Cambridge screen is in vitro; lab conditions, not humans.
The Nutrients paper is a narrative review without systematic methodology; cite it as synthesis, not pooled evidence.
The roughly 75% figure is approximate as reported and comes via press coverage of the Cambridge study.
Summarized from abstracts and press reporting; verify against the full texts before citing any claim.